LifeSci Capital Initiates Coverage On Hemab Therapeutics Hldgs with Outperform Rating, Announces Price Target of $65

Benzinga · 11/09 13:17
LifeSci Capital initiates coverage on Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Outperform rating and announces Price Target of $65.